✨ Free AI Report
Harrow Health, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Harrow Health, Inc.
Company Research

Harrow Health, Inc.: Business Overview, Financials & Competitive Analysis

Harrow Health is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company operates primarily through its subsidiary ImprimisRx, ...

Analyst-debate audio for Harrow Health, Inc.

AskCyborg analysts argue the bull and bear cases for Harrow Health, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

High-margin specialty ophthalmology platform with scalable compounding model and strategic acquisitions positioned for $1B+...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Ophthalmology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Harrow Health, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Harrow Health, Inc. Overview

Pro stress-test →

Harrow Health is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company operates primarily through its subsidiary ImprimisRx, a compounding pharmacy that creates custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings.

Strategic Profile

Pro stress-test →

By emphasizing a direct-to-prescriber model, the company circumvents many traditional barriers and costs associated with large pharmaceutical firms, allowing for reduction in drug prices and improved distribution efficiency. Harrow Health is actively involved in acquiring and licensing innovative ophthalmic technologies and products, with a multi-pronged approach that drives revenue through direct sales while strengthening its position by investing in emerging therapies.

Competitive Landscape

Pro stress-test →

Harrow competes in the specialized ophthalmology pharmaceutical segment against larger diversified pharma companies. Analyst price targets range up to $69, with multiple Buy ratings from major firms including William Blair, BTIG, and H.C. Wainwright. The direct-to-prescriber, high-margin compounding model provides differentiation versus traditional pharmaceutical distribution.

Industry Context

Harrow Health, Inc. operates in Specialty Pharmaceuticals - Ophthalmology.

Key facts

Founded: 2006 · Headquarters: San Diego, US · Revenue: $350M-$365M · Market cap: $1.85B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Harrow Health, Inc..

  • FY26 guidance of $350M-$365M revenue indicates moderation versus earlier consensus expectations of $386M
  • Strategic equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and pending Melt Pharmaceuticals acquisition expand therapeutic reach beyond core compounding
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Q3 earnings reporting continued 30% year-over-year revenue growth with $63.7M quarterly revenues
  • September 2025Entered definitive agreement for Samsung Bioepis partnership and commitment for $40M revolving credit facility
  • +1 moreTrack every material event for Harrow Health, Inc. as it happens. Explore monitoring →
Get alerted when Harrow Health, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ophthalmic PharmaceuticalsBroad ophthalmic portfolio including RESTASIS, TAVALISSE→Specialized Eye Care ProductsWide range of ocular pharmaceuticals and surgical products→Ophthalmic Therapeutic SolutionsDiversified eye care and aesthetics portfolio→

Compare Harrow Health, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Harrow Health, Inc. operates in Specialty Pharmaceuticals - Ophthalmology. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Ophthalmology research →
NEW · MCP server

Ask your AI assistant about Harrow Health, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Harrow Health, Inc. and its top competitor on Cyborg Score”
“What did Harrow Health, Inc. do this quarter?”
“Is Harrow Health, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Harrow Health, Inc. do?+
Harrow Health is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company operates primarily through its subsidiary ImprimisRx, ...
What is Harrow Health, Inc.'s Cyborg Score?+
Harrow Health, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Harrow Health, Inc.'s main competitors?+
Named competitors include Ophthalmic Pharmaceuticals, Specialized Eye Care Products, Ophthalmic Therapeutic Solutions. The full competitive landscape is in the AskCyborg report.
How can I get the full Harrow Health, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Harrow Health, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Harrow Health, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.